7 October 2024 India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative.
Recursion, a tech-bio firm seeking to decode biology to industrialize drug discovery, has announced a $50 million investment by US tech firm NVIDIA (Nasdaq: NVDA), which was executed as a private investment in public equity (PIPE). 13 July 2023
French ophthalmology biotech company Nicox has provided details of a US market survey evaluating the commercial potential of its investigational drug NCX 470, a nitric oxide (NO)-donating bimatoprost aimed at treating angle ocular or ocular hypertension. 13 July 2023
As interest in advanced therapies continues to surge, a new ophthalmic specialist focused on cell-based medicines has been launched with $70 million in series A financing. 13 July 2023
The World Health Organization (WHO) has prequalified the meningococcal meningitis vaccine developed by the Serum Institute of India (SII) and PATH, a global non-profit. 13 July 2023
The Journal of the American Medical Association (JAMA) has published key data on cytisinicline, from US specialty pharma Achieve Life Sciences. 12 July 2023
Japan’s largest drugmaker Takeda announced that it has voluntarily withdrawn the US Biologics License Application (BLA) for its dengue vaccine candidate, TAK-003. 12 July 2023
ADC Therapeutics has announced a pause in patient enrollment in the Phase II LOTIS-9 trial of Zynlonta (loncastuximab tesirine-lpyl) and rituximab (Lonca-R) in unfit or frail patients with previously-untreated diffuse large B-cell lymphoma. 12 July 2023
The recent full approval of Leqembi (lecanemab-irmb) has upped the stakes for what promises to be a particularly intriguing congress of the Alzheimer’s Association next week. 12 July 2023
US gene therapy company Avrobio today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities, joining a growing list of biotechs that have recently announced similar actions. 12 July 2023
Global drugmakers continue to defend the rights for their original drugs in Russia by participating in legal disputes with local generics’ producers, The Pharma Letter’s local correspondent reports. 12 July 2023
The Swiss subsidiary of Sino-American biotech BeiGene and Swiss pharma giant Novartis on Tuesday entered into a mutual termination and release agreement to mutually terminate the option agreement, effective immediately. 12 July 2023
Boston, USA-based Crossbow Therapeutics, a biotech developing a new class of potent and precise antibody therapies to treat a broad range of cancers, has announced an $80 million Series A funding round. 12 July 2023
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the global sector trade body, today announced a new line up for its chief executive (CEO) leadership team for the coming two years. 12 July 2023
South Korean biosimilars company Samsung Bioepis has now released the second edition of its Biosimilar Market Report, which explores latest market trends for all biosimilars commercially available in the USA. 12 July 2023
Replicate Bioscience, a company pioneering self-replicating RNA (srRNA) technology for use in infectious disease, oncology, autoimmune disease and other therapy areas, has appointed Rachael Lester as its chief business officer. 11 July 2023
Dermatology specialist Journey Medical has announced positive top-line results from two Phase III trials of its rosacea candidate, DFD-29, a formulation of minocycline hydrochloride. 11 July 2023
Yesterday after market close, US genetic medicines company 4D Molecular Therapeutics announced a license agreement with Japanese drug major Astellas Pharma. 11 July 2023
Sino-American biotech BeiGene has entered an agreement with Duality Biologic (DualityBio) to acquire an exclusive option for a global clinical and commercial license to an investigational, pre-clinical antibody-drug conjugate (ADC) therapy for patients with select solid tumors. 11 July 2023
UK-based Mestag Therapeutics has entered into a license and collaboration agreement with Merck & Co to explore new therapeutic options for inflammatory diseases. 8 October 2024
With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to the atopic dermatitis (AD) market. 8 October 2024
US antivirals specialist Gilead Sciences has released additional data from its pivotal Phase III PURPOSE 2 trial providing an overview of the efficacy and safety of twice-yearly lenacapavir. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Novo Nordisk has reached a settlement with Mylan Pharmaceuticals, now part of Viatris, putting an end to a US patent lawsuit over blockbuster diabetes treatment Ozempic (semaglutide). 8 October 2024
UK-based ViiV Healthcare, the specialist HIV company majority-owned by GSK (LSE: GSK), with Pfizer and Shionogi as shareholders, has announced a milestone in its efforts to achieve widespread international access to its therapies. 7 October 2024
Texas Attorney General Ken Paxton has filed a lawsuit against major pharmaceutical companies, including Eli Lilly (NYSE: LLY), alleging a conspiracy to artificially inflate the prices of insulin by up to 1,000%. 7 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Orchard Therapeutics has signed an exclusive distribution agreement with Turkish drugmaker Er-Kim, for the gene therapy Libmeldy (atidarsagene autotemcel). 7 October 2024
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
ABL Bio Corp on Friday revealed that it has entered into a clinical trial collaboration and supply agreement with MSD (the ex-US/Canada trading name of Merck & Co. 7 October 2024
AstraZeneca’s (Airsupra (albuterol/budesonide) has met the primary endpoint of a Phase III trial, showing a statistically significant and clinically meaningful reduction in the risk of a severe exacerbation when used as an as-needed rescue medication in response to symptoms compared to as-needed albuterol. 7 October 2024
AstraZeneca has entered into an exclusive license agreement with China’s CSPC Pharmaceutical to advance the development of an early stage, novel small molecule lipoprotein (a) (Lp(a)) disruptor that has the potential to offer additional benefits for patients with dyslipidemia. 7 October 2024
BeiGene has launched Tevimbra (tislelizumab) in the USA for the treatment of certain adults with esophageal squamous cell carcinoma (ESCC), after chemo. 7 October 2024